BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice

[1]  John Hardy,et al.  The discovery of Alzheimer‐causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis” , 2017, The FEBS journal.

[2]  D. Borchelt,et al.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease , 2016, Neurobiology of Disease.

[3]  S. Itohara,et al.  Cognitive deficits in single App knock-in mouse models , 2016, Neurobiology of Learning and Memory.

[4]  G. Tesco,et al.  The Endosome-associated Deubiquitinating Enzyme USP8 Regulates BACE1 Enzyme Ubiquitination and Degradation* , 2016, The Journal of Biological Chemistry.

[5]  D. Nicholson,et al.  Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease , 2016, Acta Neuropathologica.

[6]  B. Strooper,et al.  BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease , 2016, Trends in Neurosciences.

[7]  E. Kremmer,et al.  Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function , 2016, eLife.

[8]  F. Kametani,et al.  Amyloid β-protein oligomers upregulate the β-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons , 2015, Molecular Brain.

[9]  C. Masters,et al.  Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau , 2015, Neurotherapeutics.

[10]  M. Meyer-Luehmann,et al.  Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects β-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo* , 2015, Molecular & Cellular Proteomics.

[11]  R. Vassar,et al.  Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level , 2015, Molecular Neurodegeneration.

[12]  R. Vassar.  BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[13]  F. Checler,et al.  Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer’s disease: evidence for a pro-amyloidogenic role of MT1-MMP , 2014, Front. Aging Neurosci..

[14]  P. Osten,et al.  Genetic Inhibition of Phosphorylation of the Translation Initiation Factor eIF2α Does Not Block Aβ-Dependent Elevation of BACE1 and APP Levels or Reduce Amyloid Pathology in a Mouse Model of Alzheimer’s Disease , 2014, PloS one.

[15]  P. Wong,et al.  Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects , 2014, Journal of neurochemistry.

[16]  G. Petsko,et al.  Pharmacological chaperones stabilize retromer to limit APP processing. , 2014, Nature chemical biology.

[17]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[18]  E. Hamel,et al.  Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment , 2014, Cell Death and Differentiation.

[19]  C. Das,et al.  High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of AMSH deubiquitinase activity. , 2013, Analytical biochemistry.

[20]  D. Nicholson,et al.  The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques , 2013, Acta Neuropathologica.

[21]  A. LeBlanc.  Caspase‐6 as a novel early target in the treatment of Alzheimer's disease , 2013, The European journal of neuroscience.

[22]  R. Vassar,et al.  Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation , 2013, Molecular Neurodegeneration.

[23]  G. Tesco,et al.  BACE1 Protein Endocytosis and Trafficking Are Differentially Regulated by Ubiquitination at Lysine 501 and the Di-leucine Motif in the Carboxyl Terminus* , 2012, The Journal of Biological Chemistry.

[24]  F. Checler,et al.  BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease , 2012, Molecular Neurodegeneration.

[25]  A. Irintchev,et al.  The Injured and Regenerating Nervous System , 2012, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[26]  Sean M. Riordan,et al.  β-Site Amyloid Precursor Protein (APP)-cleaving Enzyme 1 (BACE1)-deficient Mice Exhibit a Close Homolog of L1 (CHL1) Loss-of-function Phenotype Involving Axon Guidance Defects*♦ , 2012, The Journal of Biological Chemistry.

[27]  P. Cao,et al.  Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. , 2012, ACS medicinal chemistry letters.

[28]  Parantu K. Shah,et al.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.

[29]  Yong Shen,et al.  Depletion of GGA1 and GGA3 Mediates Postinjury Elevation of BACE1 , 2012, The Journal of Neuroscience.

[30]  U. Schepers,et al.  Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons , 2012, The EMBO journal.

[31]  B. de Strooper,et al.  The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo* , 2012, The Journal of Biological Chemistry.

[32]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[33]  C. Cotman,et al.  Caspase-3 activation as a bifurcation point between plasticity and cell death , 2012, Neuroscience Bulletin.

[34]  R. Vassar,et al.  Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism , 2012, The Journal of Biological Chemistry.

[35]  H. Cai,et al.  BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer’s Disease: Differential Aβ Antibody Labeling of Early-Onset Axon Terminal Pathology , 2012, Neurotoxicity Research.

[36]  C. Masters,et al.  Decreased expression of GGA3 Protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein , 2011, Neurobiology of Disease.

[37]  G. Collingridge,et al.  Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β , 2011, Nature Neuroscience.

[38]  M. Tabaton,et al.  Amyloid-β₄₂ activates the expression of BACE1 through the JNK pathway. , 2011, Journal of Alzheimer's disease : JAD.

[39]  A. Bacci,et al.  Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease , 2011, Nature Neuroscience.

[40]  H. Cai,et al.  β‐Secretase‐1 elevation in aged monkey and Alzheimer’s disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β‐amyloid accumulation , 2010, The European journal of neuroscience.

[41]  E. Kremmer,et al.  ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons , 2010, The EMBO journal.

[42]  G. Tesco,et al.  Ubiquitin Regulates GGA3-mediated Degradation of BACE1* , 2010, The Journal of Biological Chemistry.

[43]  Steven P. Gygi,et al.  Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics , 2009, PloS one.

[44]  H. Cai,et al.  β‐Secretase‐1 elevation in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development , 2009, The European journal of neuroscience.

[45]  Huali Wang,et al.  Cognitive function of first-episode late-onset depression among Chinese elderly , 2009, Alzheimer's & Dementia.

[46]  C. Haass,et al.  Function, regulation and therapeutic properties of beta-secretase (BACE1). , 2009, Seminars in cell & developmental biology.

[47]  Y. Matsuoka,et al.  Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury , 2009, Nature Medicine.

[48]  D. Bennett,et al.  Phosphorylation of the Translation Initiation Factor eIF2α Increases BACE1 Levels and Promotes Amyloidogenesis , 2008, Neuron.

[49]  Olena Bukalo,et al.  Modulation of synaptic transmission and plasticity by cell adhesion and repulsion molecules. , 2008, Neuron glia biology.

[50]  F. Angenstein,et al.  Abnormal axonal guidance and brain anatomy in mouse mutants for the cell recognition molecules close homolog of L1 and NgCAM-related cell adhesion molecule , 2008, Neuroscience.

[51]  T. Morgan,et al.  Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase , 2008, Nature Medicine.

[52]  A. Delacourte,et al.  Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression , 2008, Proceedings of the National Academy of Sciences.

[53]  R. Vassar,et al.  BACE1 structure and function in health and Alzheimer's disease. , 2008, Current Alzheimer research.

[54]  Guiliang Tang,et al.  The Expression of MicroRNA miR-107 Decreases Early in Alzheimer's Disease and May Accelerate Disease Progression through Regulation of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 , 2008, The Journal of Neuroscience.

[55]  Manuel Buttini,et al.  Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.

[56]  A. Irintchev,et al.  Glial Scar Expression of CHL1, the Close Homolog of the Adhesion Molecule L1, Limits Recovery after Spinal Cord Injury , 2007, The Journal of Neuroscience.

[57]  R. Tanzi,et al.  Depletion of GGA3 Stabilizes BACE and Enhances β-Secretase Activity , 2007, Neuron.

[58]  R. Berry,et al.  β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis , 2007, The Journal of Neuroscience.

[59]  R. Berry,et al.  Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[60]  R. Tanzi,et al.  Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. , 2007, Neuron.

[61]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[62]  M. Sastre,et al.  Transcriptional and translational regulation of BACE1 expression—Implications for Alzheimer's disease , 2006, Progress in Neurobiology.

[63]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[64]  R. Vassar,et al.  Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[65]  B. Hyman,et al.  BACE Is Degraded via the Lysosomal Pathway* , 2005, Journal of Biological Chemistry.

[66]  G. Perry,et al.  β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways , 2005, Journal of neurochemistry.

[67]  H. Qing,et al.  Oxidative stress potentiates BACE1 gene expression and Aβ generation , 2005, Journal of Neural Transmission.

[68]  J. Trojanowski,et al.  Long-Term Accumulation of Amyloid-β, β-Secretase, Presenilin-1, and Caspase-3 in Damaged Axons Following Brain Trauma , 2004 .

[69]  J. Simpkins,et al.  Increased β-secretase activity and expression in rats following transient cerebral ischemia , 2004, Brain Research.

[70]  M. Schachner,et al.  Ectodomain Shedding of the Neural Recognition Molecule CHL1 by the Metalloprotease-disintegrin ADAM8 Promotes Neurite Outgrowth and Suppresses Neuronal Cell Death* , 2004, Journal of Biological Chemistry.

[71]  H. Cai,et al.  Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients , 2004 .

[72]  M. Citron.  Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. , 2004, Trends in pharmacological sciences.

[73]  J. Trojanowski,et al.  Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. , 2004, The American journal of pathology.

[74]  H. Cai,et al.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Simpkins,et al.  Increased beta-secretase activity and expression in rats following transient cerebral ischemia. , 2004, Brain research.

[76]  G. Ransmayr,et al.  Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer’s disease β-secretase (BACE-1) , 2004, Journal of Neural Transmission.

[77]  M. Tabaton,et al.  Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress , 2003, Neurobiology of Disease.

[78]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[79]  G. Wilcock,et al.  alpha- and beta-secretase: profound changes in Alzheimer's disease. , 2002, Biochemical and biophysical research communications.

[80]  John Calvin Reed,et al.  Multiple caspases are activated after traumatic brain injury: evidence for involvement in functional outcome. , 2002, Journal of neurotrauma.

[81]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[82]  G. Perry,et al.  Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons , 2002, Neurobiology of Disease.

[83]  C. Masters,et al.  Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .

[84]  C. Masters,et al.  Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. , 2002, Annals of neurology.

[85]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[86]  Simon C Watkins,et al.  Caspase‐3 Mediated Neuronal Death After Traumatic Brain Injury in Rats , 2000, Journal of neurochemistry.

[87]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[88]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[89]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[90]  Simon C Watkins,et al.  Increases in Bcl‐2 and cleavage of caspase‐1 and caspase‐3 in human brain after head injury , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[91]  M. Schachner,et al.  The close homologue of the neural adhesion molecule L1 (CHL1): patterns of expression and promotion of neurite outgrowth by heterophilic interactions , 1999, The European journal of neuroscience.

[92]  Brian J Cummings,et al.  Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in alzheimer's disease , 1992, Neuroscience.

[93]  P. Cras,et al.  Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.